Is It Prime Time for Alpha2-Adrenocepter Agonists in the Treatment of Withdrawal Syndromes?

Journal of Medical Toxicology

Volumn 10, Issue 4, 2014, Pages 369-381

  Albertson, Timothy E ^a,b   Chenoweth, James ^a,b   Ford, Jonathan ^a   Owen, Kelly ^a   Sutter, Mark E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alcohol withdrawal; Alpha2 agonists; Alpha2 adrenoceptor agonists; Clonidine; Dexmedetomidine; Guanfacine; Lofexidine; Nicotine withdrawal; Opioid withdrawal; Tizanidine; Withdrawal syndromes

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; CLONIDINE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; DEXMEDETOMIDINE;

ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; BRADYCARDIA; CLINICAL PRACTICE; HUMAN; SIGNAL TRANSDUCTION; WITHDRAWAL SYNDROME; OPIOID-RELATED DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ALCOHOLISM; CLONIDINE; DEXMEDETOMIDINE; HUMANS; OPIOID-RELATED DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER;

EID: 84916625745     PISSN: 15569039     EISSN: 19376995     Source Type: Journal    
DOI: 10.1007/s13181-014-0430-3     Document Type: Article

References (142)

1. Gertler R et al (2001) Dexmedetomidine: a novel sedative-analgesic agent. Proc (Bayl Univ Med Cent) 14(1):13–21
2. Fodd and Drug Administration. 2014. [cited June 2014]; Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
3. Schmidt KT, Weinshenker D (2014) Adrenaline rush: the role of adrenergic receptors in stimulant-induced behaviors. Mol Pharmacol 85(4):640–50
4. Nikolic K, Agbaba D (2012) Imidazoline antihypertensive drugs: selective i (1)-imidazoline receptors activation. Cardiovasc Ther 30(4):209–16
5. Edwards LP et al (2012) Pharmacological properties of the central antihypertensive agent, moxonidine. Cardiovasc Ther 30(4):199–208
6. Butelman ER, Woods JH (1993) Effects of clonidine, dexmedetomidine and xylazine on thermal antinociception in rhesus monkeys. J Pharmacol Exp Ther 264(2):762–9
7. Wijeysundera DN, Naik JS, Beattie WS (2003) Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. Am J Med 114(9):742–52
8. Bhana N, Goa KL, McClellan KJ (2000) Dexmedetomidine. Drugs 59(2):263–8, discussion 269–70
9. Chabot-Dore AJ, et al. Analgesic synergy between opioid and alpha-2 adrenergic receptors. Br J Pharmacol, 2014.
10. Gerlach AT, Murphy CV, Dasta JF (2009) An updated focused review of dexmedetomidine in adults. Ann Pharmacother 43(12):2064–74
11. Hosokawa K et al (2010) Dexmedetomidine sedation in children after cardiac surgery. Pediatr Crit Care Med 11(1):39–43
12. Goksu S et al (2008) Effects of dexmedetomidine infusion in patients undergoing functional endoscopic sinus surgery under local anaesthesia. Eur J Anaesthesiol 25(1):22–8
13. Wijeysundera DN, Bender JS, Beattie WS. Alpha-2 adrenergic agonists for the prevention of cardiac complications among patients undergoing surgery. Cochrane Database Syst Rev, 2009 (4): p. Cd004126.
14. Hoy SM, Keating GM (2011) Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation. Drugs 71(11):1481–501
15. Ozaki M et al (2014) Safety and efficacy of dexmedetomidine for long-term sedation in critically ill patients. J Anesth 28(1):38–50
16. Gupta P et al (2012) Safety and efficacy of prolonged dexmedetomidine use in critically ill children with heart disease*. Pediatr Crit Care Med 13(6):660–6
17. Pasin L et al (2013) Dexmedetomidine as a sedative agent in critically ill patients: a meta-analysis of randomized controlled trials. PLoS One 8(12):e82913
18. Tan JA, Ho KM (2010) Use of dexmedetomidine as a sedative and analgesic agent in critically ill adult patients: a meta-analysis. Intensive Care Med 36(6):926–39
19. Mo Y, Zimmermann AE (2013) Role of dexmedetomidine for the prevention and treatment of delirium in intensive care unit patients. Ann Pharmacother 47(6):869–76
20. Bergendahl HT et al (2004) Clonidine vs. midazolam as premedication in children undergoing adeno-tonsillectomy: a prospective, randomized, controlled clinical trial. Acta Anaesthesiol Scand 48(10):1292–300
21. Hunseler C, et al. Continuous infusion of clonidine in ventilated newborns and infants: a randomized controlled trial. Pediatr Crit Care Med. 2014.
22. Jamadarkhana S, Gopal S (2010) Clonidine in adults as a sedative agent in the intensive care unit. J Anaesthesiol Clin Pharmacol 26(4):439–45
23. Pichot C, Ghignone M, Quintin L (2012) Dexmedetomidine and clonidine: from second- to first-line sedative agents in the critical care setting? J Intensive Care Med 27(4):219–37
24. Reyes JC et al (2012) The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico. J Urban Health 89(3):519–26
25. Ruiz-Colon K et al (2014) Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: a comprehensive review of the literature. Forensic Sci Int 240:1–8
26. Perry EC (2014) Inpatient management of acute alcohol withdrawal syndrome. CNS Drugs 28(5):401–10
27. Ungur LA et al (2013) Prevention and therapy of alcohol withdrawal on intensive care units: systematic review of controlled trials. Alcohol Clin Exp Res 37(4):675–86
28. Muncie HL Jr, Yasinian Y, Oge L (2013) Outpatient management of alcohol withdrawal syndrome. Am Fam Physician 88(9):589–95
29. Reid MC, Fiellin DA, O'Connor PG (1999) Hazardous and harmful alcohol consumption in primary care. Arch Intern Med 159(15):1681–9
30. Spies CD, Rommelspacher H (1999) Alcohol withdrawal in the surgical patient: prevention and treatment. Anesth Analg 88(4):946–54
31. Kosten TR, O'Connor PG (2003) Management of drug and alcohol withdrawal. N Engl J Med 348(18):1786–95
32. Fitzgerald PJ (2013) Elevated norepinephrine may be a unifying etiological factor in the abuse of a broad range of substances: alcohol, nicotine, marijuana, heroin, cocaine, and caffeine. Subst Abuse 7:171–83
33. Awissi DK et al (2013) Alcohol withdrawal and delirium tremens in the critically ill: a systematic review and commentary. Intensive Care Med 39(1):16–30
34. Awissi DK et al (2013) Alcohol, nicotine, and iatrogenic withdrawals in the ICU. Crit Care Med 41(9):S57–68
35. Mondavio M, Ghiazza GF (1989) [Use of clonidine in the prevention of alcohol withdrawal syndrome]. Minerva Med 80(11):1233–5
36. Mertes N et al (1996) Postoperative alpha 2-adrenergic stimulation attenuates protein catabolism. Anesth Analg 82(2):258–63
37. Spies CD et al (1995) Prophylaxis of alcohol withdrawal syndrome in alcohol-dependent patients admitted to the intensive care unit after tumour resection. Br J Anaesth 75(6):734–9
38. Ip Yam PC, Forbes A, Kox WJ (1992) Clonidine in the treatment of alcohol withdrawal in the intensive care unit. Br J Anaesth 68(1):106–8
39. Wilkins AJ, Jenkins WJ, Steiner JA (1983) Efficacy of clonidine in treatment of alcohol withdrawal state. Psychopharmacology (Berl) 81(1):78–80
40. Adinoff B (1994) Double-blind study of alprazolam, diazepam, clonidine, and placebo in the alcohol withdrawal syndrome: preliminary findings. Alcohol Clin Exp Res 18(4):873–8
41. Baumgartner GR, Rowen RC (1987) Clonidine vs chlordiazepoxide in the management of acute alcohol withdrawal syndrome. Arch Intern Med 147(7):1223–6
42. Baumgartner GR, Rowen RC (1991) Transdermal clonidine versus chlordiazepoxide in alcohol withdrawal: a randomized, controlled clinical trial. South Med J 84(3):312–21
43. Manhem P et al (1985) Alcohol withdrawal: effects of clonidine treatment on sympathetic activity, the renin-aldosterone system, and clinical symptoms. Alcohol Clin Exp Res 9(3):238–43
44. Baumgartner GR (1988) Clonidine versus chlordiazepoxide in acute alcohol withdrawal: a preliminary report. South Med J 81(1):56–60
45. Bjorkqvist SE (1975) Clonidine in alcohol withdrawal. Acta Psychiatr Scand 52(4):256–63
46. Spies CD et al (1996) Therapy of alcohol withdrawal syndrome in intensive care unit patients following trauma: results of a prospective, randomized trial. Crit Care Med 24(3):414–22
47. Lansford CD et al (2008) Improved outcomes in patients with head and neck cancer using a standardized care protocol for postoperative alcohol withdrawal. Arch Otolaryngol Head Neck Surg 134(8):865–72
48. Lenzenhuber E et al (1999) Gamma-hydroxybutyrate for treatment of alcohol withdrawal syndrome in intensive care patients. A comparison between with two symptom-oriented therapeutic concepts. Anaesthesist 48(2):89–96
49. Spies CD et al (2003) Alcohol withdrawal severity is decreased by symptom-orientated adjusted bolus therapy in the ICU. Intensive Care Med 29(12):2230–8
50. Riihioja P et al (1997) Dexmedetomidine alleviates ethanol withdrawal symptoms in the rat. Alcohol 14(6):537–44
51. Muzyk AJ et al (2013) Dexmedetomidine for the treatment of alcohol withdrawal syndrome: rationale and current status of research. CNS Drugs 27(11):913–20
52. DeMuro JP et al (2012) Use of dexmedetomidine for the treatment of alcohol withdrawal syndrome in critically ill patients: a retrospective case series. J Anesth 26(4):601–5
53. Frazee EN et al (2014) Influence of dexmedetomidine therapy on the management of severe alcohol withdrawal syndrome in critically ill patients. J Crit Care 29(2):298–302
54. Tolonen J et al (2013) Dexmedetomidine in addition to benzodiazepine-based sedation in patients with alcohol withdrawal delirium. Eur J Emerg Med 20(6):425–7
55. Rayner SG et al (2012) Dexmedetomidine as adjunct treatment for severe alcohol withdrawal in the ICU. Ann Intensive Care 2(1):12
56. Mazanikov M et al (2013) Dexmedetomidine impairs success of patient-controlled sedation in alcoholics during ERCP: a randomized, double-blind, placebo-controlled study. Surg Endosc 27(6):2163–8
57. Mueller SW et al (2014) A randomized, double-blind, placebo-controlled dose range study of dexmedetomidine as adjunctive therapy for alcohol withdrawal. Crit Care Med 42(5):1131–9
58. Savel RH, Kupfer Y (2014) Using dexmedetomidine as adjunctive therapy for patients with severe alcohol withdrawal syndrome: another piece of the puzzle. Crit Care Med 42(5):1298–9
59. Bou Khalil R (2011) Tizanidine for alcohol withdrawal treatment. Med Hypotheses 77(4):548–9
60. Brunning J, Mumford JP, Keaney FP (1986) Lofexidine in alcohol withdrawal states. Alcohol Alcohol 21(2):167–70
61. Cushman P Jr et al (1985) Alcohol withdrawal syndromes: clinical management with lofexidine. Alcohol Clin Exp Res 9(2):103–8
62. Keaney F et al (2001) A double-blind randomized placebo-controlled trial of lofexidine in alcohol withdrawal: lofexidine is not a useful adjunct to chlordiazepoxide. Alcohol Alcohol 36(5):426–30
63. Muzyk AJ et al (2011) Role of alpha2-agonists in the treatment of acute alcohol withdrawal. Ann Pharmacother 45(5):649–57
64. Rehni AK, Jaggi AS, Singh N (2013) Opioid withdrawal syndrome: emerging concepts and novel therapeutic targets. CNS Neurol Disord Drug Targets 12(1):112–25
65. Krantz MJ, Mehler PS (2004) Treating opioid dependence. Growing implications for primary care. Arch Intern Med 164(3):277–88
66. Gold MS, Redmond DE Jr, Kleber HD (1978) Clonidine blocks acute opiate-withdrawal symptoms. Lancet 2(8090):599–602
67. Mannelli P et al (2012) The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal. Am J Drug Alcohol Abuse 38(3):200–5
68. Monterubbianesi MC et al (2012) High opioid dosage rapid detoxification of cancer patient in palliative care with the Raffaeli model. J Opioid Manag 8(5):292–8
69. O'Mara K, Gal P, Davanzo C (2010) Treatment of neonatal withdrawal with clonidine after long-term, high-dose maternal use of tramadol. Ann Pharmacother 44(7–8):1342–4
70. Deutsch ES, Nadkarni VM (1996) Clonidine prophylaxis for narcotic and sedative withdrawal syndrome following laryngotracheal reconstruction. Arch Otolaryngol Head Neck Surg 122(11):1234–8
71. Malhotra A et al (1997) Clonidine versus withdrawal using an opioid in in-patient opioid detoxification. Eur Addict Res 3(3):146–149
72. Ziaaddini H, Nasirian M, Nakhaee N (2012) Comparison of the efficacy of buprenorphine and clonidine in detoxification of opioid-dependents. Addict Health 4(3–4):79–86
73. Hartmann F et al (1991) Comparison of acetorphan with clonidine for opiate withdrawal symptoms. Am J Psychiatry 148(5):627–9
74. Akhondzadeh S et al (2000) Double-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawal. J Clin Pharm Ther 25(5):347–53
75. Gossop M (1988) Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend 21(3):253–9
76. Strang J, Bearn J, Gossop M (1999) Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. Am J Addict 8(4):337–48
77. Gish EC et al (2010) Lofexidine, an {alpha}2-receptor agonist for opioid detoxification. Ann Pharmacother 44(2):343–51
78. Washton AM, Resnick RB, Geyer G (1983) Opiate withdrawal using lofexidine, a clonidine analogue with fewer side effects. J Clin Psychiatry 44(9):335–7
79. Yu E et al (2008) A phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. Drug Alcohol Depend 97(1–2):158–68
80. McCambridge J et al (2007) In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone. Drug Alcohol Depend 88(1):91–5
81. Howells C et al (2002) Prison based detoxification for opioid dependence: a randomised double blind controlled trial of lofexidine and methadone. Drug Alcohol Depend 67(2):169–76
82. Doosti F et al (2013) Traditional Chinese and Indian medicine in the treatment of opioid-dependence: a review. Avicenna J Phytomed 3(3):205–15
83. Liu TT et al (2009) A meta-analysis of Chinese herbal medicine in treatment of managed withdrawal from heroin. Cell Mol Neurobiol 29(1):17–25
84. Shi J et al (2008) A comparative clinical study of the effects of the traditional Chinese medicine Jinniu capsules and lofexidine on acute heroin withdrawal symptoms. Am J Drug Alcohol Abuse 34(6):792–800
85. Lin SK et al (1997) Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal. Drug Alcohol Depend 48(2):127–33
86. Carnwath T, Hardman J (1998) Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal. Drug Alcohol Depend 50(3):251–4
87. Walsh SL, Strain EC, Bigelow GE (2003) Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans. Addiction 98(4):427–39
88. San L et al (1990) Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. Br J Addict 85(1):141–7
89. Muga R et al (1990) Comparative effectiveness of alpha-2 adrenergic agonists (clonidine-guanfacine) in the hospital detoxification of opiate addicts. Med Clin (Barc) 94(5):169–72
90. Pinelli A, Trivulzio S, Spezia R (1998) Effects of tizanidine administration on precipitated opioid withdrawal signs in rats. Drug Alcohol Depend 50(1):81–8
91. Koyuncuoglu H et al (1992) Effects of tizanidine on morphine physical dependence: attenuation and intensification. Pharmacol Biochem Behav 42(4):693–8
92. Sos I et al (2000) [Tizanidine in the treatment of acute withdrawal symptoms in heroin dependent patients]. Orv Hetil 141(15):783–6
93. Koyuncuoglu H (1995) The combination of tizanidine markedly improves the treatment with dextromethorphan of heroin addicted outpatients. Int J Clin Pharmacol Ther 33(1):13–9
94. Davies MF et al (2003) Dexmedetomidine fails to cause hyperalgesia after cessation of chronic administration. Anesth Analg 96(1):195–200, table of contents
95. Hayashi Y, Guo TZ, Maze M (1996) Hypnotic and analgesic effects of the alpha2-adrenergic agonist dexmedetomidine in morphine-tolerant rats. Anesth Analg 83(3):606–10
96. Oschman A, McCabe T, Kuhn RJ (2011) Dexmedetomidine for opioid and benzodiazepine withdrawal in pediatric patients. Am J Health Syst Pharm 68(13):1233–8
97. Tobias JD (2008) Subcutaneous dexmedetomidine infusions to treat or prevent drug withdrawal in infants and children. J Opioid Manag 4(4):187–91
98. Tobias JD (2006) Dexmedetomidine to treat opioid withdrawal in infants following prolonged sedation in the pediatric ICU. J Opioid Manag 2(4):201–5
99. Finkel JC, Johnson YJ, Quezado ZM (2005) The use of dexmedetomidine to facilitate acute discontinuation of opioids after cardiac transplantation in children. Crit Care Med 33(9):2110–2
100. Tobias JD, Berkenbosch JW, Russo P (2003) Additional experience with dexmedetomidine in pediatric patients. South Med J 96(9):871–5
101. Vega L et al (2013) Prevention of opioid withdrawal syndrome after pediatric heart transplantation: usefulness of dexmedetomidine. Rev Esp Cardiol (Engl Ed) 66(7):593–5
102. Upadhyay SP et al (2011) Dexmedetomidine infusion to facilitate opioid detoxification and withdrawal in a patient with chronic opioid abuse. Indian J Palliat Care 17(3):251–4
103. Multz AS (2003) Prolonged dexmedetomidine infusion as an adjunct in treating sedation-induced withdrawal. Anesth Analg 96(4):1054–5, table of contents
104. Nasr DA et al (2011) Ultra-rapid opiate detoxification using dexmedetomidine under general anesthesia. J Opioid Manag 7(5):337–44
105. Belgrade M, Hall S (2010) Dexmedetomidine infusion for the management of opioid-induced hyperalgesia. Pain Med 11(12):1819–26
106. Gowing L et al (2014) Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 3:Cd002024
107. Gowing LR et al (2002) Alpha2-adrenergic agonists in opioid withdrawal. Addiction 97(1):49–58
108. Honey BL et al (2009) Alpha2-receptor agonists for treatment and prevention of iatrogenic opioid abstinence syndrome in critically ill patients. Ann Pharmacother 43(9):1506–11
109. Benowitz NL (2010) Nicotine addiction. N Engl J Med 362(24):2295–303
110. Markou A (2008) Review. Neurobiology of nicotine dependence. Philos Trans R Soc Lond B Biol Sci 363(1507):3159–68
111. D'Souza MS, Markou A (2011) Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments. Addict Sci Clin Pract 6(1):4–16
112. D’Souza MS Markou A. The “stop” and “go” of nicotine dependence: role of GABA and glutamate. Cold Spring Harb Perspect Med. 2013. 3 (6).
113. Yamada H, Bruijnzeel AW (2011) Stimulation of alpha2-adrenergic receptors in the central nucleus of the amygdala attenuates stress-induced reinstatement of nicotine seeking in rats. Neuropharmacology 60(2–3):303–11
114. Lucidarme O et al (2010) Nicotine withdrawal and agitation in ventilated critically ill patients. Crit Care 14(2):R58
115. Hughes JR (2007) Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res 9(3):315–27
116. Glassman AH et al (1984) Cigarette craving, smoking withdrawal, and clonidine. Science 226(4676):864–6
117. Gourlay S et al (1994) A placebo-controlled study of three clonidine doses for smoking cessation. Clin Pharmacol Ther 55(1):64–9
118. Glassman AH et al (1993) Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin Pharmacol Ther 54(6):670–9
119. Hao W, Young D (1988) Effect of clonidine on cigarette cessation and in the alleviation of withdrawal symptoms. Br J Addict 83(10):1221–6
120. Franks P, Harp J, Bell B (1989) Randomized, controlled trial of clonidine for smoking cessation in a primary care setting. Jama 262(21):3011–3
121. Ornish SA, Zisook S, McAdams LA (1988) Effects of transdermal clonidine treatment on withdrawal symptoms associated with smoking cessation. A randomized, controlled trial. Arch Intern Med 148(9):2027–31
122. Prochazka AV et al (1992) Transdermal clonidine reduced some withdrawal symptoms but did not increase smoking cessation. Arch Intern Med 152(10):2065–9
123. Cervantes Escarcega JL, Guadalajara Boo JF (1992) Effect of transdermal therapy with clonidine on suppression symptoms secondary to smoking cessation. Arch Inst Cardiol Mex 62(5):435–40
124. Hilleman DE et al (1989) Double-blind, placebo-controlled, evaluation of transdermal clonidine in smoking cessation. Chest 96(1):2085
125. Niaura RBR, Goldstein MG, Murphy JK, Abrams DB (1996) Transdermal clonidine for smoking cessation: a double-blind randomized dose–response study. Exp Clin Psychopharmacol 4(3):285–291
126. Hilleman DE et al (1993) Randomized, controlled trial of transdermal clonidine for smoking cessation. Ann Pharmacother 27(9):1025–8
127. Sees KL, Stalcup SA (1989) Combining clonidine and nicotine replacement for treatment of nicotine withdrawal. J Psychoactive Drugs 21(3):355–9
128. Cahill K et al (2013) Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 5:Cd009329
129. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev, 2004 (3): p. Cd000058.
130. Hansson L et al (1973) Blood pressure crisis following withdrawal of clonidine (Catapres, Catapresan), with special reference to arterial and urinary catecholamine levels, and suggestions for acute management. Am Heart J 85(5):605–10
131. Whalen LD, et al. Long-term dexmedetomidine use and safety profile among critically ill children and neonates. Pediatr Crit Care Med, 2014.
132. Kukoyi A et al (2013) Two cases of acute dexmedetomidine withdrawal syndrome following prolonged infusion in the intensive care unit: report of cases and review of the literature. Hum Exp Toxicol 32(1):107–10
133. FDA Med Watch. [cited 2014 8/30]; Available from: http://www.fda.gov/Safety/Medwatch/Safety Information/ucm233675.htm.
134. Cushman P Jr (1987) Clonidine and alcohol withdrawal. Adv Alcohol Subst Abuse 7(1):17–28
135. Gold MS et al (1980) Opiate withdrawal using clonidine. A safe, effective, and rapid nonopiate treatment. Jama 243(4):343–6
136. Charney DS et al (1981) The clinical use of clonidine in abrupt withdrawal from methadone. Effects on blood pressure and specific signs and symptoms. Arch Gen Psychiatry 38(11):1273–7
137. Jasinski DR, Johnson RE, Kocher TR (1985) Clonidine in morphine withdrawal. Differential effects on signs and symptoms. Arch Gen Psychiatry 42(11):1063–6
138. Bearn J, Gossop M, Strang J (1996) Randomised double-blind comparison of lofexidine and methadone in the in-patient treatment of opiate withdrawal. Drug Alcohol Depend 43(1–2):87–91
139. Kahn A et al (1997) Double-blind study of lofexidine and clonidine in the detoxification of opiate addicts in hospital. Drug Alcohol Depend 44(1):57–61
140. Bearn J, Gossop M, Strang J (1998) Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification. Drug Alcohol Depend 50(3):227–32
141. Bearn J et al (2001) The impact of naloxone/lofexidine combination treatment on the opiate withdrawal syndrome. Addict Biol 6(2):147–156
142. Beswick T et al (2003) The effectiveness of combined naloxone/lofexidine in opiate detoxification: results from a double-blind randomized and placebo-controlled trial. Am J Addict 12(4):295–305